hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06389734 id: B-ER-111-470 briefTitle: Combining Manual Soft Tissue Release and Exercise Training in COPD: the Effect on LF, EC, and CAF overallStatus: COMPLETED date: 2023-03-02 date: 2024-02-02 date: 2024-02-02 date: 2024-04-29 date: 2024-04-29 name: National Cheng Kung University class: OTHER briefSummary: The potential effects of combining manual soft tissue release and physical exercise training on lung function, exercise capacity, and cardiac autonomic function in patients with moderate and severe chronic obstructive pulmonary disease were investigated. conditions: Chronic Obstructive Pulmonary Disease conditions: Manual Soft Tissue Release conditions: Exercise Training conditions: Lung Function conditions: Exercise Capacity conditions: Cardiac Autonomic Function studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The study population will be randomized and separated in two groups, experimental and control group. primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 70 type: ACTUAL name: Manual soft tissue release name: Myofascial release name: Exercise training measure: Forced expiratory volume in 1 s (FEV1) measure: forced vital capacity (FVC) measure: FEV1/FVC ratio measure: expiratory reserve volume (ERV) measure: functional residual capacity (FRC) measure: inspiratory capacity (IC) measure: inspiratory reserve volume (IRV), measure: residual volume (RV) measure: total lung capacity (TLC) measure: tidal volume (TV) measure: vital capacity (VC) measure: Rate of perceived exertion (RPE) measure: Oxygen consumption (VO2) measure: oxygen saturation measure: heart rate (HR) measure: blood pressure (BP) measure: Diaphragmatic mobility measure: Cardiac Autonomic Function measure: six minute walk test (6-MWT) measure: maximal expiratory pressure (MEP) measure: maximal inspiratory pressure (MIP) measure: St. George's Respiratory Questionnaire (SGRQ) measure: fatigue severity scale (FSS) measure: Modified Medical Research Council (mMRC) measure: 36-Item Short Form Health Survey (SF-36) sex: ALL minimumAge: 30 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Cheng Kung University city: Tainan zip: 701 country: Taiwan lat: 22.99083 lon: 120.21333 hasResults: False
nctId: NCT06389721 id: 2024-0145 id: NCI-2024-03672 type: OTHER domain: NCI-CTRP Clinical Registry briefTitle: Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy overallStatus: NOT_YET_RECRUITING date: 2024-10-31 date: 2025-01-31 date: 2027-01-31 date: 2024-04-29 date: 2024-04-29 name: M.D. Anderson Cancer Center class: OTHER briefSummary: Cohort 1: To track the onset and progression of a condition called chemotherapy-induced peripheral neuropathy (CIPN).
Cohort 2: To track the onset and progression of a condition called chemotherapy-induced peripheral neuropathy (CIPN) and to test a certain type of experimental neuromodulation (stimulation of the brain) with a device called a closed-loop brain-computer interface (clBCI) to see if can help to prevent pain due to CIPN. conditions: Chemotherapy-induced Peripheral Neuropathy studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 45 type: ESTIMATED name: Electroencephalogram (EEG) measure: Safety and adverse events (AEs) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: MD Anderson Cancer Center city: Houston state: Texas zip: 77030 country: United States name: Sarah Prinsloo, PHD role: CONTACT phone: 713-563-9627 email: sprinsloo@mdanderson.org name: Sarah Prinsloo, PHD role: PRINCIPAL_INVESTIGATOR lat: 29.76328 lon: -95.36327 hasResults: False
nctId: NCT06389708 id: VEVUS-HF briefTitle: Evaluation of VEXUS Score of Patients With Heart Failure in the Intensive Care Unit. overallStatus: NOT_YET_RECRUITING date: 2024-05-15 date: 2024-12-15 date: 2025-01-15 date: 2024-04-29 date: 2024-04-29 name: Inonu University class: OTHER briefSummary: Heart failure is a syndrome that progresses with symptoms and signs caused by cardiac dysfunction and results in a shortened life expectancy (1). Acute heart failure resulting in hospitalization is a significant cause of morbidity and mortality. With the increase in the severity of the disease and rapid advances in the treatment of heart failure, these patients are frequently hospitalized and monitored in intensive care. (2) Five years after diagnosis, mortality can be up to 67%. Additionally, it is known that patients with heart failure are hospitalized on average once a year after diagnosis. (3) In a multicenter study, it constituted 14% of 3000 cardiac patients admitted to intensive care units. Additionally, due to longer ICU stays, these patients accounted for 33% of total inpatient days. An increasing number of heart failure patients require intensive care due to respiratory failure, regardless of left ventricular ejection fraction. Heart failure accounts for approximately one-third of patient days in intensive care units, and this burden is increasing. This shows that attention should be paid to the quality of care for patients requiring critical care. (2) Multidisciplinary programs have been implemented to deal with the high prevalence. However, the optimal follow-up frequency is unknown. Therefore, some tools are needed to improve patient prognosis (3). Neutrophil gelatinase-associated lipocalin (NGAL) is a biomarker whose values in both urine and plasma have been associated with acute kidney injury (AKI). Although NGAL is an early specific biomarker for AKI, it has not yet come into routine use, but is frequently used in clinical and experimental studies (4). Venous load ultrasonography score (VExUS) is a new systemic congestion scoring method based on inferior vena cava dilation and pulsed wave Doppler (PW-Doppler) morphology of the hepatic, portal and renal veins. It has been proposed as a score to assess systemic congestion. conditions: Heart Failure conditions: Acute Kidney Injury studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED measure: VEXUS measure: MORTALİTY measure: AKI sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06389695 id: CP-2023-03 id: NYM032D01 type: OTHER domain: National Medical Products Administration briefTitle: Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM032 in Patients overallStatus: RECRUITING date: 2024-05 date: 2024-12 date: 2024-12 date: 2024-04-29 date: 2024-04-29 name: Norroy Bioscience Co., LTD class: INDUSTRY briefSummary: 68Ga-NYM032 is a PSMA-targeting small-molecular radiotracer for PET/CT imaging of prostate cancer, which is needed for clinical trial to be conducted conditions: Prostate Cancer studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 10 type: ESTIMATED name: 68Ga-NYM032 injection measure: Incidence of Adverse Events sex: MALE minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Affliated Hospital of Jiangnan University status: RECRUITING city: Wuxi state: Jiangsu zip: 214000 country: China name: Chunjing Yu role: CONTACT phone: 15312238622 email: ycj_wxd1978@163.com lat: 31.56887 lon: 120.28857 hasResults: False
nctId: NCT06389682 id: CP-2023-02 briefTitle: Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM005 in Patients overallStatus: RECRUITING date: 2024-05 date: 2024-12 date: 2024-12 date: 2024-04-29 date: 2024-04-29 name: Norroy Bioscience Co., LTD class: INDUSTRY briefSummary: 68Ga-NYM005 is a CAIX-targeting small-molecular radiotracer for PET/CT imaging of clear cell renal cell carcinoma conditions: Clear Cell Renal Cell Carcinoma Metastatic studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 12 type: ESTIMATED name: 68Ga-NYM005 injection measure: Incidence of Adverse Events sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Affliated Hospital of Jiangnan University status: RECRUITING city: Wuxi state: Jiangsu zip: 214000 country: China name: Chunjing Yu role: CONTACT phone: 15312238622 email: ycj_wxd1978@163.com lat: 31.56887 lon: 120.28857 hasResults: False
nctId: NCT06389669 id: Inonu LTI briefTitle: Is Low Flow Anaesthesia Feasible? overallStatus: NOT_YET_RECRUITING date: 2024-05-15 date: 2024-08-15 date: 2024-09-15 date: 2024-04-29 date: 2024-04-29 name: Inonu University class: OTHER briefSummary: Although low-flow anaesthesia (LFA) has been described for many years and its benefits are known, its clinical use has been limited. Concerns about the risk of hypoxia contributed to this situation. Although the risk of hypoxia is almost prevented with advanced anaesthesia machines, the use of LFA has not reached the desired levels. However, in recent years, as adverse developments related to climate change have started to affect us all, LFA has started to be on the agenda of anaesthetists again. In this study, our aim is to examine the feasibility of its clinical use in order to popularise the use of LFA. conditions: Feasibility of Low Flow Anaesthesia in Clinical Use conditions: Factors Affecting Oxygen Consumption studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 600 type: ESTIMATED measure: Feasibility of Low Flow Anaesthesia measure: Factors affecting oxygen consumption sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Inonu Univercity city: Malatya zip: 44280 country: Turkey lat: 38.35018 lon: 38.31667 hasResults: False
nctId: NCT06389656 id: 1K23DK135791-01 type: NIH link: https://reporter.nih.gov/quickSearch/1K23DK135791-01 briefTitle: Addressing Weight Bias Internalization to Improve Adolescent Weight Management Outcomes acronym: SWIFT overallStatus: RECRUITING date: 2024-04-08 date: 2025-02 date: 2025-02 date: 2024-04-29 date: 2024-04-29 name: The Miriam Hospital class: OTHER briefSummary: Weight stigma and weight bias internalization (WBI) are common among adolescents at higher weight statuses. WBI is associated with negative physical and mental health outcomes. The current study aims to test intervention for weight stigma and WBI in conjunction with an evidence-based adolescent weight management program. Adolescents (ages 13-17) will participate in a 20-week program tailored to improve WBI and weight-related health behaviors in tandem. Primary outcomes are feasibility and acceptability of the developed intervention, assessed following the 20-week intervention. conditions: Body Weight conditions: Weight Bias conditions: Weight Stigma conditions: Weight studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Open trial primaryPurpose: TREATMENT masking: NONE count: 24 type: ESTIMATED name: Behavioral Weight Management name: Weight Bias Internalization measure: Total score on an adapted version of the Acceptability of Intervention Measure (AIM) measure: In depth qualitative feedback from teens regarding intervention acceptability and feasibility measure: Attendance rates at intervention sessions measure: Retention rate for intervention sessions measure: Total score on the Modified Weight Bias Internalization Scale (WBIS-M) measure: Total score on the Weight Self-Stigma Questionnaire (WSSQ) measure: Total score on the weight-related teasing sub-scale of the Perception of Teasing Scale (POTS) measure: Total score on the competency-related teasing subscale of the Perception of Teasing Scale (POTS) measure: Anthropometrics sex: ALL minimumAge: 13 Years maximumAge: 17 Years stdAges: CHILD facility: The Miriam Hospital status: RECRUITING city: Providence state: Rhode Island zip: 02903 country: United States name: Katherine Darling, PhD role: CONTACT phone: 401-793-8688 email: katherine_darling@brown.edu name: Andrea M Grenga, BA role: CONTACT phone: 401-793-8997 email: agrenga@lifespan.org lat: 41.82399 lon: -71.41283 hasResults: False
nctId: NCT06389643 id: 11/WIM/2021 briefTitle: Comparison of Safety and Efficacy of Four-Point Scleral Intraocular Lens Fixation and Yamane Techniques overallStatus: COMPLETED date: 2021-03-19 date: 2022-09-14 date: 2023-09-19 date: 2024-04-29 date: 2024-04-29 name: Military Institute od Medicine National Research Institute class: OTHER briefSummary: Comparison of safety and efficacy of two scleral fixation intraocular lens (IOL) methods of four-point scleral fixation ( Akreos AO60) and the Yamane technique (AcrySof MA60AC) conditions: Aphakia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: INVESTIGATOR count: 50 type: ACTUAL name: Four-point scleral fixation of Akreos AO60 IOL name: Sutureless scleral fixation of AcrySof MA60AC IOL with Yamane technique measure: BCVA measure: RE measure: ECC measure: Number of complications sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Military Institute of Medicine - National Research Institute city: Warsaw zip: 04-141 country: Poland lat: 52.22977 lon: 21.01178 hasResults: False
nctId: NCT06389630 id: 0012 briefTitle: Evaluation of the Efficiency of Two Different Teaching Methods in Safe Subcutaneous Injection Skills acronym: EETDTMSSİS overallStatus: NOT_YET_RECRUITING date: 2024-04-29 date: 2024-11-20 date: 2025-01-20 date: 2024-04-29 date: 2024-04-29 name: Kocaeli Sağlık ve Teknoloji Üniversitesi class: OTHER briefSummary: Subject: Subcutaneous (SC) insulin injection is frequently used in the treatment of Type 2 Diabetes patients. Complications such as pain, ecchymosis, hematoma, lipoatrophy and lipohypertrophy are frequently observed after SC injections. These complications that develop due to incorrect injection application negatively affect the use of injection application areas, change body image and negatively affect drug absorption. In order to reduce and prevent complications related to SC insulin injection, it is very important to gain the skill of safe SC insulin injection. It is stated that there are a limited number of studies on which of the teaching methods used in sick individuals are effective. In the national and international literature, no study has been found evaluating the effect of SC injection skill teaching based on video-supported training and low-fidelity simulation model applications on disease management in individuals diagnosed with Type 2 Diabetes Mellitus. In this regard, the research was planned as an experimental design in order to examine the effectiveness of video-supported training and low-fidelity simulation model-based teaching in gaining safe insulin injection skills via SC. For this purpose; It is aimed to evaluate the effect of two different skill teaching methods on the patient's SC injection ability, complication management and blood glucose level.
Design: A pretest-posttest two-group, quasi-experimental design will be used in the study. conditions: Complication of Injection studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 82 type: ESTIMATED name: video-assisted training group name: low fidelity simulation model group measure: subcutaneous injection skills measure: ecchymosis measure: hematoma measure: lipoarthrrophy measure: lipohypertrophy measure: pain measure: blood glucose level sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06389617 id: USM/JEPeM/KK/24010061 briefTitle: Different Doses of Intravenous Administered Dexamethasone Effecting Brachial Plexus Supraclavicular Block overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-11-30 date: 2024-12-30 date: 2024-04-29 date: 2024-04-29 name: Hospital Universiti Sains Malaysia class: OTHER briefSummary: To compare the analgesic properties of ultrasound guided supraclavicular block using ropivacaine 0.5% in arteriovenous fistula creation when used in combination with intravenous administered dexamethasone at 4mg and 8 mg as an adjuvant conditions: End Stage Renal Failure studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 50 type: ESTIMATED name: supraclavicular block with 20mls of Ropivacaine 0.5% and Intravenous administered dexamethasone measure: To compare the difference of onset time between sensory and motor block of supraclavicular block between ropivacaine with IV dexamethasone 4mg and ropivacaine with IV dexamethasone 8mg measure: To compare the difference in duration of analgesia between supraclavicular block with ropivacaine and IV dexamethasone 4mg with ropivacaine and IV dexamethasone 8mg measure: To compare the duration difference of the return of motor block between supraclavicular block using ropivacaine with IV dexamethasone 4mg and ropivacaine with IV dexamethasone 8mg sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06389604 id: NL86367.068.24 briefTitle: Preparing for Heat Waves - Enhancing Human Thermophysiological Resilience acronym: Prep4heat overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-12 date: 2024-12 date: 2024-04-29 date: 2024-04-29 name: Maastricht University Medical Center class: OTHER briefSummary: As the ongoing progression of climate change exposes individuals to elevated temperatures and an escalating frequency of extreme heat events, the risk of more intense and prolonged heat waves raises significant concerns for public health, particularly among vulnerable populations. The physiological response to acute heat stress involves involuntary thermolytic reactions that may strain the cardiovascular system, especially in individuals with pre-existing vulnerabilities. Heat acclimation has been identified as a potential strategy to enhance thermoregulation and mitigate the adverse effects of heat stress. While existing research primarily focuses on athletes and military, this study aims to investigate the impact of a practical heat acclimation strategy, combining passive and active heat exposure, on thermophysiological, cardiovascular and metabolic parameters in healthy overweight adults. The study targets a population at increased risk for heat-related complications, seeking to provide realistic guidelines for broader application when a heat wave appears on the weather forecast. conditions: Body Temperature Changes conditions: Heat Exposure conditions: Heat Stress conditions: Hyperthermia studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Non-randomized, within subject experiemental trial primaryPurpose: PREVENTION masking: NONE maskingDescription: No blinding due to nature of intervention count: 12 type: ESTIMATED name: Heat acclimation measure: Core temperature measure: Skin temperature measure: Sweat rate measure: Heart rate measure: Blood pressure measure: Skin blood flow measure: Energy expenditure measure: Substrate oxidation measure: Plasma metabolites measure: Brain blood flow measure: Flow-mediated dilation sex: ALL minimumAge: 60 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06389591 id: OCR44973 briefTitle: RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM) overallStatus: NOT_YET_RECRUITING date: 2024-12 date: 2027-12 date: 2028-12 date: 2024-04-29 date: 2024-04-29 name: University of Florida class: OTHER briefSummary: This is a Phase I study to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in adult patients with recurrent glioblastoma. conditions: Recurrent Glioblastoma studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 24 type: ESTIMATED name: pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1) name: RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2) measure: Percentage of vaccines meeting release criteria in the DLT window during the first three vaccines measure: Incidence of investigational treatment related toxicities sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: UF Health city: Gainesville state: Florida zip: 32608 country: United States name: Marcia Hodik role: CONTACT phone: 352-273-9000 email: marcia.hodik@neurosurgery.ufl.edu name: Ashley Ghiaseddin, MD role: PRINCIPAL_INVESTIGATOR lat: 29.65163 lon: -82.32483 hasResults: False
nctId: NCT06389578 id: HZNP-TEP-103 briefTitle: A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease overallStatus: COMPLETED date: 2022-07-14 date: 2023-02-28 date: 2023-09-12 date: 2024-04-29 date: 2024-04-29 name: Horizon Therapeutics USA, Inc. class: INDUSTRY briefSummary: The main goal of this study is to learn how teprotumumab will be processed in the body (Pharmacokinetics) subcutaneously and whether it is safe and tolerable after administration into adult patients with thyroid eye disease. conditions: Thyroid Eye Disease studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 16 type: ACTUAL name: Teprotumumab measure: Pharmacokinetics (PK): Area Under the Curve (AUC) of Teprotumumab measure: PK: Maximum Serum Concentration (Cmax) of Teprotumumab measure: Number of Participants With Adverse Events (AE) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Bascom Palmer Eye Institute - University of Miami city: Miami state: Florida zip: 33136 country: United States lat: 25.77427 lon: -80.19366 facility: Barnes Jewish Hospital Washington University city: Saint Louis state: Missouri zip: 63108 country: United States lat: 38.62727 lon: -90.19789 facility: Neuro-Eye Clinical Trials city: Bellaire state: Texas zip: 77401 country: United States lat: 29.70579 lon: -95.45883 hasResults: False
nctId: NCT06389565 id: 2024p000857 briefTitle: Pilot Randomized Clinical Trial of Change My Story overallStatus: NOT_YET_RECRUITING date: 2025-01-01 date: 2025-12-31 date: 2026-06-30 date: 2024-04-29 date: 2024-04-29 name: Massachusetts General Hospital class: OTHER name: University of Ibadan briefSummary: Psychological distress and depression are common among young people living with HIV (Y-PLWH) and negatively impact medication adherence and disease control. In low- and middle-income countries, this problem is compounded by the lack of trained mental health professionals on the provider side and the requirement of frequent clinic-based visits imposing greater cost, inconvenience, and stigma for patients. Change My Story, is a theory-grounded, interactive narrative game designed to address the key drivers of depression and psychological distress among Y-PLWH in Nigeria. This pilot hybrid implementation-effectiveness randomized controlled trial (RCT) will compare Change My Story combined with PST to PST alone among 80 Y-PLWH with depression or psychological distress. conditions: Hiv conditions: Depression conditions: Psychological Distress studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: PARTICIPANT count: 80 type: ESTIMATED name: Problem Solving Therapy name: Change My Story measure: Engagement measure: Satisfaction measure: Feasibility 1 measure: Feasibility 2 measure: Feasibility 3 measure: Feasibility 4 measure: Feasibility 5 measure: Feasibility 6 measure: Feasibility 7 measure: Acceptability 1 measure: Acceptability 2 measure: Acceptability 3 measure: Acceptability 4 measure: Acceptability 5 measure: Remission of depression. measure: Remission of psychological distress. measure: ART adherence measure: Viral suppression sex: ALL minimumAge: 16 Years maximumAge: 24 Years stdAges: CHILD stdAges: ADULT hasResults: False